Pericarditis Drugs Market Outlook 2024-2031: Robust 5.2% CAGR as Global Guidelines Drive Shift from Steroids to IL-1 Biologics, Fueled by AI Imaging and Digital Health Innovations

Global Pericarditis Drugs Market reached US$ 544.4 million in 2023 and is expected to reach US$ 816.6 million by 2031, growing at a CAGR of 5.2% during the forecast period 2024-2031.

Pericarditis Drugs Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/pericarditis-drugs-market?un

Industry News of USA and Japan:

USA

• Kiniksa's ARCALYST (rilonacept) commercial momentum accelerated in Q2 2025, with net product revenue reaching $156.8M, and full-year guidance raised to $625-$640M.

• Updated U.S. clinical practice guidance (Aug 2025) now explicitly endorses IL-1 inhibitors such as rilonacept and anakinra for patients not responding to first-line NSAID/colchicine therapy.

• Real-world registry analyses highlight a growing shift away from corticosteroids toward IL-1 pathway therapies for recurrent pericarditis in clinical practice.

• The FDA updated mRNA COVID-19 vaccine labeling in June 2025 to better describe the risks of myocarditis and pericarditis, keeping the condition under active regulatory monitoring.

• Investment and development activity includes Cardiol Therapeutics advancing CardiolRx in pivotal programs, alongside broader R&D into novel anti-inflammatory candidates for pericarditis.

Japan

• A nationwide JROAD-DPC analysis (mid-2025) reported trends in idiopathic pericarditis management and outcomes across Japanese teaching hospitals.

• The Japanese Circulation Society's 2025 guideline updates incorporated international advances, promoting earlier recognition and standardized care pathways for pericarditis.

• Academic centers in Japan are increasingly publishing clinical experiences with IL-1 blockade and advanced imaging for pericarditis, indicating strong clinician interest.

• Clinical research collaborations in Japan leverage both national registry data (JROAD) and international trial networks to shape future drug use and health-technology assessments.

• Japanese cardiology practices are adopting AI-driven cardiovascular imaging tools to improve diagnosis and monitoring of pericardial disease, supporting targeted-therapy integration.

Key Players:

• Kiniksa Pharmaceuticals,

• Cardiol Therapeutics,

• Bayer AG,

• Haleon group of companies,

• Johnson & Johnson Services, Inc.,

• Hikma Pharmaceuticals USA Inc.,

• Pfizer Inc.,

• Catalent, Inc.,

• Airgas, Inc

• Takeda Pharmaceutical Company Limited

Growth Forecast Projected:

The Global Pericarditis Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Pericarditis Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=pericarditis-drugs-market

Market Segmentation:

➤ By Drug Type: Nonsteroidal anti-inflammatory drugs (NSAIDs), Colchicine, Others

➤ By Disease Type: Acute Pericarditis, Chronic Pericarditis, Recurrent Pericarditis, Idiopathic Pericarditis

➤ By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/pericarditis-drugs-market

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the Pericarditis Drugs Market?

➠ Who are the leading manufacturers in the global Digital Diabetes industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global Digital Diabetes industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the Pericarditis Drugs Market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.